Adiumentum Capital Management

Atara Biotherapeutics is an off-the-shelf T-cell immunotherapy company based in South San Francisco, California, focused on developing innovative treatments for patients with cancer, autoimmune diseases, and viral infections. The company's lead product, tabelecleucel (tab-cel), is currently in Phase III clinical trials for treating Epstein-Barr virus-associated post-transplant lymphoproliferative disorder, with additional development for other EBV-related hematologic malignancies and solid tumors, such as nasopharyngeal carcinoma. Atara is also advancing next-generation CAR T immunotherapies, addressing various conditions including mesothelin-targeted therapies for solid tumors and treatments for B-cell lymphomas. Other notable candidates include therapies for multiple sclerosis and several viral infections. The company collaborates with esteemed institutions such as Memorial Sloan Kettering Cancer Center and Bayer AG to enhance its research and development efforts. Founded in 2012, Atara Biotherapeutics is committed to transforming the treatment landscape for serious diseases through its robust clinical and scientific initiatives.

Atara Biotherapeutics is an off-the-shelf T-cell immunotherapy company based in South San Francisco, California, focused on developing innovative treatments for patients with cancer, autoimmune diseases, and viral infections. The company's lead product, tabelecleucel (tab-cel), is currently in Phase III clinical trials for treating Epstein-Barr virus-associated post-transplant lymphoproliferative disorder, with additional development for other EBV-related hematologic malignancies and solid tumors, such as nasopharyngeal carcinoma. Atara is also advancing next-generation CAR T immunotherapies, addressing various conditions including mesothelin-targeted therapies for solid tumors and treatments for B-cell lymphomas. Other notable candidates include therapies for multiple sclerosis and several viral infections. The company collaborates with esteemed institutions such as Memorial Sloan Kettering Cancer Center and Bayer AG to enhance its research and development efforts. Founded in 2012, Atara Biotherapeutics is committed to transforming the treatment landscape for serious diseases through its robust clinical and scientific initiatives.